

Drug Monograph

Drug/Drug **Doryx MPC[®] (doxycycline hyclate) delayed release tablet/**
 Class: **Tetracyclines**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Doryx MPC[®] is now available in a delayed release tablet that contains 120 mg of doxycycline hyclate.

Manufacturer: Mayne Pharma USA, Greenville, NC 27834

Indications: Doryx MPC[®] is indicated for the treatment of rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax including inhalational anthrax (post-exposure), and for prophylaxis of malaria. It is also indicated as an alternative treatment for selected infections when penicillin is contraindicated, and as adjunctive therapy for acute intestinal amebiasis and severe acne.

Costs: \$12.50 per tablet of Doryx MPC[®]. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation:

<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> PDL

Type of PA Criteria:

<input type="checkbox"/> Increased Risk of ADE	<input checked="" type="checkbox"/> Under Solicitation
<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer Pharm.D.
 Date: November 7, 2016